Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

161.50
-7.0200-4.17%
Pre-market: 160.79-0.7100-0.44%04:01 EDT
Volume:1.82M
Turnover:296.64M
Market Cap:21.67B
PE:-46.09
High:169.60
Open:166.35
Low:160.23
Close:168.52
52wk High:176.58
52wk Low:53.40
Shares:134.20M
Float Shares:129.78M
Volume Ratio:1.03
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-97.24
PE(LYR):-48.64

Loading ...

Guardant Health announces U.S. FDA approved Guardant360 CDx

TIPRANKS
·
Jun 11

Guardant Health Announces FDA Approval of Guardant360 Cdx as Companion Diagnostic for Boehringer Ingelheim’s Hernexeos®

THOMSON REUTERS
·
Jun 11

Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?

Simply Wall St.
·
Jun 10

Guardant Health Co-CEO Helmy Eltoukhy disposes of common shares worth $12.54 million

Reuters
·
Jun 09

Guardant Health CFO Michael Brian Bell disposes of 2,000 common shares worth $257,240.60

Reuters
·
Jun 09

Guardant Health Inc : Mizuho Raises Target Price to $175 From $135

THOMSON REUTERS
·
Jun 08

Guardant Health director Steve Krognes disposes of 9,294 common shares worth $1.23 million

Reuters
·
Jun 06

Guardant Health Initiated at Buy by Goldman Sachs

Dow Jones
·
Jun 05

Guardant Health initiated with a Buy at Goldman Sachs

TIPRANKS
·
Jun 05

Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)

TIPRANKS
·
Jun 05

Guardant Health director Meghan Verena Joyce reports disposal of common shares worth $1.27 million

Reuters
·
Jun 05

A new blood test can help detect colon cancer, but it's not as good as the test you hate to take

Dow Jones
·
Jun 05

GH Research announces publication of Phase 2a results for mebufotenin

TIPRANKS
·
Jun 04

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GlobeNewswire
·
Jun 04

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

GlobeNewswire
·
Jun 03

Guardant Health Raised to Outperform From In-Line by Evercore ISI Group

Dow Jones
·
Jun 02

Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95

MT Newswires Live
·
Jun 02

Guardant Health Shares Rise 2.2% Premarket After Evercore Isi Upgrades Stock, Raises PT

THOMSON REUTERS
·
Jun 02

Guardant Health Inc : Evercore Isi Raises to Outperform From in Line; Raises Target Price to $160 From $95

THOMSON REUTERS
·
Jun 02

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

GlobeNewswire
·
Jun 02